|Bid||10.50 x 1800|
|Ask||11.61 x 1300|
|Day's Range||10.64 - 11.64|
|52 Week Range||10.64 - 53.46|
|Beta (5Y Monthly)||1.55|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.60|
Subscribe to Yahoo Finance Plus to view Fair Value for PSNLLearn more
MENLO PARK, Calif., January 06, 2022--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer and population sequencing, today reported unaudited preliminary revenue for the fourth quarter and full year ended December 31, 2021.
MENLO PARK, Calif., December 28, 2021--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management will participate in the 24th Annual Needham Virtual Growth Conference on Tuesday, January 11, 2022.
This week we saw the Personalis, Inc. ( NASDAQ:PSNL ) share price climb by 11%. But that's not enough to compensate for...